A bibliometric evaluation of the top 100 cited articles on ocrelizumab.

BACKGROUND: To analyze the 100 most cited articles (T100) on ocrelizumab using bibliometric methods to determine the current situation and identify research hotspots. METHODS: Articles with "ocrelizumab" in their title were searched for in the Web of Science (WoS) database, identifying 900 articles. After the exclusion criteria were applied, 183 original articles and reviews were obtained. The T100 were selected from among these articles. Data on these articles (author, source, institution, country, scientific category, citation number, and citation density) were analyzed. RESULTS: The number of articles showed a fluctuating upward trend from 2006 to 2022. The total number of citations for the T100 ranged from two to 923. The average number of citations per article was 45.11. The most articles were published in 2021 (n = 31). The "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis" study (T1) was the most cited article among the T100 and had the highest annual average number of citations. T1, T2, and T3 were clinical trials on treating multiple sclerosis. The USA was the most productive and influential research country, with 44 articles. Multiple Sclerosis and Related Disorders was the most productive journal (n = 22). Clinical neurology ranked first among the WoS categories (n = 70). Hauser Stephen and Kappos Ludwig were the most influential authors, with 10 articles each. Biotechnology company Roche was at the top of the publication list, with 36 articles. CONCLUSION: This study's results can give researchers an idea about current developments and research collaborations on ocrelizumab. These data can help researchers easily obtain publications that have become classics. We conclude that the clinical and academic communities have shown a growing interest in ocrelizumab for treating primary progressive multiple sclerosis in recent years.

Content and quality analysis of videos about multiple sclerosis on social media: The case of YouTube.

BACKGROUND: YouTube (YT) has grown into the largest online video platform across the world. Known to have more than two billion users of all ages, YT also serves as an important educational tool and information source for patients and their families. YT videos have the potential to influence patients' understanding of their diagnoses and treatment decision-making. METHODS: Videos were identified using the keywords "multiple sclerosis," "multiple sclerosis treatment," "relapsing remitting MS," and "central demyelinating disorder" in the YT search bar. For each search term, the top 30 videos were reviewed. The videos were analyzed by two independent raters using the DISCERN and Global Quality Scale (GQS) scoring systems. Qualitative and quantitative data were recorded for each video. RESULTS: A total of 99 videos were analyzed. The mean DISCERN score was 43.44 out of 75 possible points, and the mean Global Quality Scale (GQS) score was 2.77 out of 5 possible points. Of all the videos, 14.1, 29.3, 15.2, and 29.3% were categorized as very poor, poor, moderate, good, and excellent, respectively. Videos that included qualitative features such as clear information; information related to symptomatology, etiology, diagnosis, treatment, treatment response, and epidemiology; and diagrams and radiological images had significantly higher scale scores. Audience engagement parameters were significantly higher for videos containing animation, treatment response, and radiological images. CONCLUSION: We maintain that sufficient, reliable, and useful content is not provided for those seeking information on YT about MS. Everyone seeking information about MS should always verify information provided in YT videos using more reliable sources of information. Video producers should optimize their videos to contain high-quality and reliable data and to attract larger audiences.

Reduced Short-Latency Afferent Inhibition Indicates Impaired Sensorimotor Integrity During Migraine Attacks.

BACKGROUND AND OBJECTIVE: Migraine attacks disrupt sensory information processing and may also disturb sensorimotor integration. This prospective pilot study aimed to assess the sensorimotor integration and inhibitory circuitry in the sensorimotor cortex using short-latency afferent inhibition (SAI) paradigm in migraine. METHODS: Twenty-five migraine without aura patients (10 interictal, 5 preictal, 10 ictal) and 16 healthy controls were enrolled. SAI was elicited by combining the right median nerve electrical stimulation and left motor cortical magnetic stimulation at the 21-millisecond interval. Mean motor evoked potential (MEP) amplitude ratio, recorded from right abductor pollicis muscle after single and conditioned stimulations, was calculated as SAI. RESULTS: Average MEP inhibition ratio after single and conditioned stimuli in healthy controls was not significantly different from interictal patients (45.1% ± 20.3% vs 44.5% ± 14.75% [P = .93]). However, SAI was significantly reduced during preictal/prodromal (-14.6% ± 42.8% [P = .002]) and ictal/headache (-7.4% ± 31.1% [P = .0001]) periods of migraine compared to healthy controls. CONCLUSION: Pronounced decrease in SAI during preictal and ictal periods in migraine was shown for the first time. Instead of inhibition to a conditioned stimulus, facilitation in the sensorimotor cortex was detected both ictally and preictally. Preictal SAI results suggest the presence of increased excitability state several hours prior to the headache phase. This phenomenon could be related to the cortical hyperresponsivity to sensory stimuli and cognitive disturbances accompanying migraine attacks as SAI is modulated by cholinergic activity.

Impaired short- and long-latency afferent inhibition in amyotrophic lateral sclerosis.

INTRODUCTION: To test the hypothesis of impaired cholinergic activity in amyotrophic lateral sclerosis (ALS), we studied short- and long-latency afferent inhibition (SAI and LAI). METHODS: The ulnar nerve was stimulated at the wrist preceding transcranial magnetic stimulation (TMS), 21 ms for SAI and 200 ms for LAI, in 21 patients and 17 control subjects. Short-interval intracortical inhibition (SICI) and cognitive function was assessed in ALS patients using automatic threshold tracking and the Montreal Cognitive Assessment (MoCA). RESULTS: The SAI paradigm resulted in inhibition in all control subjects, whereas inhibition was observed in 13 of 21 (62%) patients. Mean SAI and LAI values were significantly reduced in ALS. No significant correlation existed between afferent inhibition and other neurophysiological data. The MoCA was normal in all but 1 patient. DISCUSSION: LAI and SAI are both impaired in ALS, probably unrelated to increased cortical excitability or cognitive dysfunction. Muscle Nerve 59:699-704, 2019.